Open AccessBook
Myasthenia Gravis
Huub Oosterhuis
- 01 Jan 1997
2.4K
About: The article was published on 01 Jan 1997. and is currently open access. The article focuses on the topics: Myasthenia gravis & Ocular myasthenia.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Progress in the treatment of myasthenia gravis.
TL;DR: In this paper, the authors characterize modern treatment algorithms that are adapted to disease severity and introduce the principle of escalating treatment strategies for MG, which is the standard base-line treatment, in particular in cases where high doses of GCS would be needed to maintain remission.
Establishment of a Human Thymic Myoid Cell Line : Phenotypic and Functional Characteristics
A Wakkach,Sandrine Poea,Eric Chastre,Christian Gespach,Florence Lecerf,Sabine De La Porte,Socrates J. Tzartos,Alain Coulombe,Sonia Berrih-Aknin +8 more
TL;DR: The immortalization of stromal cells from human thymus by using a plasmid vector encoding the SV40 T oncogene resulted in a new line of myoid cells that expressed both the fetal and adult forms of muscle acetylcholine receptor (AChR) at the mRNA level, as well as the myogenic transcription factor MyoD1.
50
Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis.
TL;DR: In this paper, the most widely used clinical classifications and scales in myasthenia gravis (MG) have been described, and the authors highlight the choice of outcome measures in published and ongoing trials, and denote whether trial efficacy was reached on these outcomes.
Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals
TL;DR: Nasal administration of AChR in ongoing EAMG induced selective suppression of Th1 functions, i.e. IFN‐γ and IgG2b production, but no influence on Th2 cell functions, which may result in the production of less myasthenic anti‐AChR antibodies and contribute to the amelioration of EAMGs severity.
50
An integrated intelligent computing model for the interpretation of EMG based neuromuscular diseases
TL;DR: An integrated model of RBR, CBR and ANN is developed in which RBR is used to hierarchically correlate the sign and symptom of the disease and also to compute cumulative confidence factor (CCF) of the diseases.
49